Body Composition
Body composition research encompasses fat-mass reduction, lean-mass preservation, and visceral-adipose-tissue (VAT) targeting. Incretin agonists (the long-acting GLP-1 agonist, the GLP-1 / GIP dual agonist, the triple-receptor incretin agonist) drive whole-body fat reduction via central appetite suppression. GHRH analogs (tesamorelin) preferentially target visceral adipose without significant subcutaneous-fat change. Body composition is the highest-volume search cluster in the broader metabolic-medicine category.
